Abstract:Recent advances have demonstrated the crucial role of the complement system in cancer, with its impact being context‐dependent and influenced by the site of complement activation. This underscores the need to stratify patients based on the intra‐ versus extracellular location of complement proteins to optimize therapeutic strategies. Malignant cells are part of a complex network within the tumor microenvironment, where their interaction with host cells and soluble mediators, including complement components, is pivotal. The complement system, known for its role in immune defense and homeostasis, exhibits a dual effect on cancer progression. This dichotomy arises from its antitumoral opsonophagocytosis and cytotoxicity versus its protumoral chronic inflammation mediated by the C5a/C5aR1 axis, influencing antitumor T‐cell responses. Recent studies have revealed distinct co‐expression patterns of complement genes in various cancer types, correlating with prognosis. Notably, some cancers exhibit co‐regulated overexpression of complement genes associated with poor prognosis, while others show favorable outcomes. However, significant intra‐patient heterogeneity further complicates this classification. Moreover, the involvement of locally produced and intracellular complement proteins adds complexity to the tumor microenvironment dynamics. This review highlights the unique interplay of complement components within different cancers and patient cohorts, showing that "one size does not fit all", for complement in cancer. It summarizes the clinical trials for complement targeting in cancer, emphasizing the need for tailored therapeutic approaches. By elucidating the mechanistic basis of complement's context‐dependent role, this review aims to facilitate the development of personalized cancer therapies, ultimately improving patient care and outcomes.

The C5a/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response

Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.

Blockade of C5a Receptor Unleashes Tumor-Associated Macrophage Antitumor Response and Enhances CXCL9-dependent CD8+ T Cell Activity

Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?

CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity

Data from Autocrine Complement Inhibits IL10-Dependent T-cell–Mediated Antitumor Immunity to Promote Tumor Progression

The CCR2/MCP-1 Chemokine Pathway and Lung Adenocarcinoma

Cancer cells impair monocyte-mediated T cell stimulation to evade immunity

C5aR1 is a Master Regulator in Colorectal Tumorigenesis Via Immune Modulation

Impaired function of dendritic cells within the tumor microenvironment

The complement system as a target in cancer immunotherapy

Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance

Blocking C5aR Signaling Promotes the Anti-Tumor Efficacy of PD-1/PD-L1 Blockade

Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity

Inducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasis

CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses

Monocytic myeloid-derived suppressor cells home to tumor-draining lymph nodes via CCR2 and locally modulate the immune response

Data from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Complement in cancer: untangling an intricate relationship